MARY CURLL: Open Payments
NPI 1174528319 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,834 in 84 payments from 18 companies in 2025. Trend: 2023 $2,466 · 2024 $2,972 · 2025 $1,834
Food & beverage: $1,834
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $300 |
| Bayer Healthcare Pharmaceuticals Inc. | 13 | $269 |
| ABBVIE INC. | 15 | $246 |
| AstraZeneca Pharmaceuticals LP | 4 | $227 |
| Amgen Inc. | 10 | $144 |
| Novo Nordisk Inc | 5 | $124 |
| Otsuka America Pharmaceutical, Inc. | 6 | $117 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $71 |
| Lilly USA, LLC | 3 | $71 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
Products named: CAPLYTA, Kerendia, VRAYLAR, AIRSUPRA, REXULTI, OTEZLA, JARDIANCE, MOUNJARO.
Industry payments across TX — which companies pay providers there.
